Recombinant EGFR (Panitumumab Biosimilar) anticorps

N° du produit ABIN7200662

Détail du produit anti-EGFR (Panitumumab Biosimilar) anticorps

Antigène: EGFR (Panitumumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp EGFR (Panitumumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Fonction: Panitumumab Biosimilar, Human EGFR/ErbB-1/HER1 Monoclonal Antibody

Specificité: The monoclonal antibody panitumumab biosimilar specifically binds to the human EGFR, ErbB-1 and HER1.

Attributs du produit: Recombinant Humanized IgG2 Monoclonal Antibody.

Purification: Protein A affinity column

Pureté: > 95% by SDS-PAGE under reducing conditions and HPLC.

Stérilité: 0.2 μm filtered

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method.

Immunogène: The monoclonal antibody panitumumab biosimilar was produced in the Panitumumab biosimilar CHO stable cell line.

Isotype: IgG2 kappa

Information d'application

Indications d'application: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by panitumumab.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Agent conservateur: Without preservative

Conseil sur la manipulation: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Stock: -20 °C

Stockage commentaire: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Date de péremption: 12 months

Détails sur EGFR (Panitumumab Biosimilar)

Antigène: EGFR (Panitumumab Biosimilar)

Abstract: EGFR (Panitumumab Biosimilar) Produits

Classe de substances: Biosimilar

Sujet: Panitumumab, a fully anti-EGFR (epidermal growth factor receptor, EGF receptor, ErbB-1 and HER1 in humans) human monoclonal antibody, is used for the treatment of refractory EGFR-expressing metastatic colorectal cancer in patients with non-mutated (wild-type) KRAS".